PLoS ONE (Jan 2021)

Cannabis is associated with clinical but not endoscopic remission in ulcerative colitis: A randomized controlled trial.

  • Timna Naftali,
  • Lihi Bar-Lev Schleider,
  • Fabiana Scklerovsky Benjaminov,
  • Fred Meir Konikoff,
  • Shelly Tartakover Matalon,
  • Yehuda Ringel

DOI
https://doi.org/10.1371/journal.pone.0246871
Journal volume & issue
Vol. 16, no. 2
p. e0246871

Abstract

Read online

BackgroundCannabis is often used by patients with ulcerative colitis, but controlled studies are few. We aimed to assess the effect of cannabis in improving clinical and inflammatory outcomes in ulcerative colitis patients.MethodsIn a double-blind, randomized, placebo-controlled trial, patients received either cigarettes containing 0.5 g of dried cannabis flowers with80mgTetrahydrocannabinol (THC)or placebo cigarettes for 8 weeks. Parameters of disease including Lichtiger disease activity index, C reactive protein (CRP), calprotectin, Mayo endoscopic score and quality of life (QOL) were assessed before, during and after treatment.ResultsThe study included 32 patients. Mean age was 30 years, 14 (43%) females. Lichtiger index improved in the cannabis group from 10.9 (IQR 9-14) to5 (IQR 1-7), (pConclusionShort term treatment with THC rich cannabis induced clinical remission and improved quality of life in patients with mild to moderately active ulcerative colitis. However, these beneficial clinical effects were not associated with significant anti-inflammatory improvement in the Mayo endoscopic score or laboratory markers for inflammation.(clinicaltrials.gov NCT01040910).